Fibrosis in the Bone Marrow: A Spotlight on Myelofibrosis Pathology

Health Apr 24, 2025 6 Add to Reading List

Myelofibrosis (MF) is an uncommon and chronic blood cancer that results in the replacement of healthy bone marrow with fibrous (scar) tissue, disrupting normal blood cell formation. It is classified under myeloproliferative neoplasms (MPNs)—a group of disorders defined by abnormal blood cell production. When MF occurs on its own, it is known as primary myelofibrosis, whereas cases developing from existing conditions like polycythemia vera (PV) or essential thrombocythemia (ET) are called secondary MF (commonly referred to as post-PV or post-ET MF).

Epidemiological Trends in Myelofibrosis (2020–2034, 7MM)

Epidemiological analysis includes various parameters:

Total and Diagnosed Prevalent Population
Breakdown by MF Type
Risk-Level Categorization
Age-Wise Distribution
Genetic Mutation Status (e.g., JAK2)
Transplant Eligibility Status

Key Highlights

In 2023, around 56,000 individuals across the seven major markets (7MM) were reported to be living with myelofibrosis, with cases expected to increase by 2034.
Within the EU4 and the UK, Germany had the highest burden, whereas the UK had the lowest number of diagnosed cases.
In the U.S., the majority of diagnoses in 2023 were classified as high-risk.
Approximately 75% of U.S. cases were identified as primary MF.
People aged 70 and above made up the largest patient population, accounting for nearly 12,000 cases.
Around 60% of U.S. patients had the JAK2 mutation, a key biomarker in MF.

For an at-a-glance view of these trends, explore this Myelofibrosis Market Infographic.

Market Snapshot: Myelofibrosis in the 7MM

The Myelofibrosis market reached a valuation of roughly USD 1.8 billion in the 7MM in 2023, with strong momentum projected through the forecast period.

Growth Accelerators

OMJJARA stands out for being approved for both treatment-naïve and pre-treated MF patients.
The introduction of VONJO, specifically for patients with low platelet counts, has broadened treatment accessibility.

Ongoing Challenges

Diagnostic delays remain a concern due to symptom similarity with other fibrotic diseases such as idiopathic pulmonary fibrosis.
The competitive landscape is intensifying with the arrival of innovative, disease-modifying therapies.

Dive deeper into current market trends in this Detailed Myelofibrosis Market Report.